Skip to main content

Table 5 Overall survival

From: Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma

  ------------------------------Time to Death (days)------------------------------
  Analysis with censoring of patients who began a new therapya Analysis without censoring of patients who began a new therapyb
  Median (95% CI), days c Median (95% CI), days c
Overall Survival (N = 74) 230.0 (143.0, 401.0) 230.0 (148.0, 330.0)
Exploratory Analyses   
Overall survival by:   
M classification   
   M1a (n = 7) NE (270.0, NE) 340.0 (270.0, NE)
   M1b (n = 13) NE (230.0, NE) NE
   M1c (n = 54) 148.0 (116.0, 297.0) 148.0 (117.0, 239.0)
Prior chemotherapy   
   With (n = 40) 165.0 (118.0, 297.0) 165.0 (143.0, 297.0)
   Without (n = 34) 401.0 (138.0, NE) 340.0 (139.0, NE)
Dose escalation of talabostat   
   With (n = 44) 330.0 (153.0, NE) 330.0 (165.0, NE)
   Without (n = 30) 139.0 (81.0, 270.0) 139.0 (81.0, 230.0)
Initial cisplatin dose   
   100 mg/m2 (n = 35) 230.0 (109.0, NE) 239.0 (116.0, 401.0)
   75 mg/m2 (n = 39) 209.0 (148.0, NE) 209.0 (148.0, 340.0)
  1. CI = confidence interval; NE = non-estimable
  2. a Patients not dying had their survival time censored on the last date of known contact. Patients who began another anti-melanoma therapy were censored on the start date of the new anti-melanoma treatment.
  3. b Patients not dying had their survival time censored on the last date of known contact. Patients who began another anti-melanoma therapy were not censored because of the new therapy.
  4. c In many cases, there was insufficient information to calculate the median or the upper limit for the CI for these data.
  5. d ITT population.